234 related articles for article (PubMed ID: 30213802)
1. Utility of an "Allosteric Site-Impaired" M
Moo EV; Sexton PM; Christopoulos A; Valant C
Mol Pharmacol; 2018 Nov; 94(5):1298-1309. PubMed ID: 30213802
[TBL] [Abstract][Full Text] [Related]
2. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
3. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
[TBL] [Abstract][Full Text] [Related]
4. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
[TBL] [Abstract][Full Text] [Related]
5. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
[TBL] [Abstract][Full Text] [Related]
6. Role of Conserved Tyrosine Lid Residues in the Activation of the M
Pham V; Habben Jansen MCC; Thompson G; Heitman LH; Christopoulos A; Thal DM; Valant C
Mol Pharmacol; 2023 Sep; 104(3):92-104. PubMed ID: 37348914
[TBL] [Abstract][Full Text] [Related]
7. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
Avlani V; May LT; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
[TBL] [Abstract][Full Text] [Related]
9. M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding.
Keller M; Tränkle C; She X; Pegoli A; Bernhardt G; Buschauer A; Read RW
Bioorg Med Chem; 2015 Jul; 23(14):3970-90. PubMed ID: 25650309
[TBL] [Abstract][Full Text] [Related]
10. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of selective positive allosteric modulators of antagonists for the M
Korczynska M; Clark MJ; Valant C; Xu J; Moo EV; Albold S; Weiss DR; Torosyan H; Huang W; Kruse AC; Lyda BR; May LT; Baltos JA; Sexton PM; Kobilka BK; Christopoulos A; Shoichet BK; Sunahara RK
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2419-E2428. PubMed ID: 29453275
[TBL] [Abstract][Full Text] [Related]
12. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
Valant C; Felder CC; Sexton PM; Christopoulos A
Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
[TBL] [Abstract][Full Text] [Related]
13. Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors.
Tränkle C; Mohr K
Mol Pharmacol; 1997 Apr; 51(4):674-82. PubMed ID: 9106634
[TBL] [Abstract][Full Text] [Related]
14. New insight into active muscarinic receptors with the novel radioagonist [³H]iperoxo.
Schrage R; Holze J; Klöckner J; Balkow A; Klause AS; Schmitz AL; De Amici M; Kostenis E; Tränkle C; Holzgrabe U; Mohr K
Biochem Pharmacol; 2014 Aug; 90(3):307-19. PubMed ID: 24863257
[TBL] [Abstract][Full Text] [Related]
15. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
May LT; Lin Y; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
[TBL] [Abstract][Full Text] [Related]
16. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
17. Allosteric binding sites on muscarinic acetylcholine receptors.
Wess J
Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
[TBL] [Abstract][Full Text] [Related]
18. Allosteric modulators and selective agonists of muscarinic receptors.
Holzgrabe U; De Amici M; Mohr K
J Mol Neurosci; 2006; 30(1-2):165-8. PubMed ID: 17192667
[TBL] [Abstract][Full Text] [Related]
19. Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors.
Jakubík J; Randáková A; Zimčík P; El-Fakahany EE; Doležal V
Sci Rep; 2017 Jan; 7():40381. PubMed ID: 28091608
[TBL] [Abstract][Full Text] [Related]
20. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors.
Voigtländer U; Jöhren K; Mohr M; Raasch A; Tränkle C; Buller S; Ellis J; Höltje HD; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):21-31. PubMed ID: 12815157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
